Richard Makara - 15 Jun 2022 Form 3 Insider Report for Cara Therapeutics, Inc. (CARA)

Role
VP, Head of Accting;Controller
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Issuer symbol
CARA
Transactions as of
15 Jun 2022
Net transactions value
$0
Form type
3
Filing time
16 Jun 2022, 17:12:19 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CARA Common Stock 6,083 15 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 20,000 $17.41 Direct F2
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 20,000 $13.51 Direct F2
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 20,000 $14.18 Direct F2
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 30,000 $16.10 Direct F3
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 30,000 $16.36 Direct F4
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 30,000 $18.93 Direct F5
holding CARA Stock Option (Right to Buy) 15 Jun 2022 Common Stock 20,000 $10.46 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,083 shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. (1) 50% of the RSUs will vest on December 15, 2022; and (2) the remaining 50% of the RSUs will vest on June 15,2023, subject to the Reporting Person's continued service to the Issuer on each such date.
F2 Fully vested and immediately exercisable.
F3 The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F4 The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F5 The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on April 3, 2021, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F6 The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney